5 Biotech Earnings Under The Microscope This Week
As most market participants already know, earnings season is now underway.
Whether one is an investor or trader, trading stocks or options, a company's earnings release can be very profitable for some, while detrimental to others.
Although all sectors and industries are under the microscope when earnings start to flow in, one in particular comes into greater focus this earnings season – biotechnology – the industry that's been one of the market's top performers for the entire bull run.
The reason why the biotech industry might be watched a little more closely as of late is due to fears of a possible biotech bubble.
This upcoming week brings a handful of biotech names to keep an eye on, including a couple big dogs.
Tuesday, April 21
Tuesday's after market close brings the release of Amgen, Inc. (NASDAQ: AMGN)'s report.
Analyst expectations are for $2.07/share.
Wednesday, April 22
The market will be looking for $1.33/share from Alexion and $1.01/share from Amag.
Friday, April 24
Investors and analysts are wanting to see $3.91/share from Biogen and $0.25/share from ImmunoGen.
Obviously, investors must conduct their own due diligence before investing in any stock, but whether one is looking to avoid or capitalize on earnings season, the biotechs are names to watch.
The biotech stocks considered for this review were confined to those trading over $10 per share and traded at least 500,000 shares a day based on a 90-day average.
Image Credit: Public Domain
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Tags: earnings season